This clinical trial is studying a treatment for Systemic Lupus Erythematosus, an autoimmune disease where the body’s immune system attacks its own tissues. The study will test a new medication called obexelimab to determine if it can reduce disease activity in people with this condition. The medication will be given through subcutaneous injection, which means it is injected under the skin.

The main purpose of this research is to evaluate how well obexelimab works compared to placebo in reducing lupus disease activity. During the study, participants will also receive standard lupus treatments, which may include antimalarial medications, corticosteroids like prednisolone, or other medications that suppress the immune system.

The study will last 24 weeks, during which participants will receive either obexelimab or placebo injections. Throughout the study, doctors will monitor various aspects of the disease, including skin symptoms, joint problems, and overall disease activity. They will also track how the treatment affects participants’ fatigue levels and general well-being. The maximum daily dose of obexelimab will be 250 mg, with a total maximum dose of 6000 mg over the course of treatment.